Belgium gets in on blocks with UCB, ThromboGenics
Bank of America Merrill Lynch launched its second Belgian healthcare deal in two days with a €223m secondary sale of UCB shares on Thursday following a €78m primary sale for small-cap ThromboGenics 24 hours earlier.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts